The host bone marrow stem cell repopulation is crucial to the permanent tolerance in 50% liver transplantation

The host bone marrow stem cell repopulation is crucial to the permanent tolerance in 50% liver transplantation | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The host bone marrow stem cell repopulation is crucial to the permanent tolerance in 50% liver transplantation guoyong chen, gaofeng Tang, huibo zhao, sidong wei, xiaoyan guo, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1505625/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The severe toxicities and side-effects derived from lifelong anti-rejection therapy following organ transplantation necessitates operational tolerance, a immunosuppression-free state in which the allograft functions well and no immunological rejections occur, no operational tolerance is in use globally. Here we introduce that operational tolerance, based on the hypertrophy to hyperplasia transition upon liver regeneration, is early acquired and permanently maintained in 50% adult rat liver allograft transplantation through the host bone marrow stem cell repopulation and 9-day cyclosporine A use. Compared with whole and partial liver transplantations as the controls, longer-term survivals (over 500 days) were observed in the tolerant hosts (p=0.001), the allograft functioned well and no acute or chronic rejections were confirmed by histology examinations. Further study revealed that the allograft was reinstituted by host-derived stem cells marked with CD34, which migrated, repopulated and differentiated after mobilization. However donor-specific hypo-response was not achieved through skin transplantation, indicating no adaptive immune activity occurrence. Our protocol is characteristic of targeting the allograft and non-immunological intervention, offering a novel avenue to operational tolerance induction which is of highly clinical relevance Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Introduction Liver transplantation (LT) is well accepted as the only life-saving treatment for benign end-stage liver diseases, metabolic liver diseases and liver tumors. Chronic immunosuppression is standard-of-care to preserve the donor allografts, bringing about the disreputably adverse effects associated with systemic toxicities, lower quality of life and greater cost burden 1–3 . It was reported that the recipients had hardly gained longer-term survival post- LT for decades 2 . Operational tolerance can overcome major histocompatibility complex (MHC) barriers and permit complete withdrawal of immunosuppressants; it holds a promise as the Holy Grail. Peter Medawar first realized skin graft tolerance using fetal mice with immature immunology to make transplant a reality 4 . Calne et al reported spontaneous tolerance induction using the liver allograft heterotopically placed in pigs 5 . Later Houssin et al also successfully induced tolerance using an accessory semi-allograft in rats while the host total liver removal was performed after the graft implantation to spontaneously accept other grafts like the heart and skin from the same donor, demonstrating that the liver is immunologically privileged 6 . Both protocols did not mimic clinical practice. Great immunology progresses have advanced our understanding of rejection as a bi-directional immune activity in nature between the host and the graft. All strategies of tolerance induction targeted the host and immune reaction, deletion or anergy of T cells, blockade of costimulatory signals and adoptive transfer of regulatory T cells were designed and carried out 7,8, , these proof-of-principle studies cannot be extrapolated to the clinic. Starzl pioneered human LT and pinpointed out chimerism was the frequent state of the long-living recipients 9 . Currently it is documented that macrochimerism achieved by hematopoietic cell transplantation from the solid organ donor is essential to operational tolerance, but maintaining macrochimerism is challenging due to continuous immune deletion or destruction by the host over time, and hematopoietic cell transplantation will incur life-threatening complications like severe infections and graft versus host disease 10,11 , it is noted that clinical trials for this protocol are under way. Feng et al reported a higher rate of spontaneous tolerance of parental partial allograft in highly selective pediatric recipients, suggesting that liver regeneration was possibly attributable to tolerance 12 . The liver has a unique regenerative capacity to restore his native mass following major resection, this unique phenomenon like an elephant in the room is neglected in tolerance induction. Liver regeneration exists in three forms or sources: hepatocytes (accounting for 80% of parenchyma cells), liver-resident progenitors (< 2%) and extra-hepatic stem cells. Generally, the basic premise of hepatocyte proliferation is the intact hepatocytes upon hepatectomy; when intra-hepatic cell proliferation was refrained, extra-hepatic progenitors contributed to this process 13–15 . Here we deployed unique liver regeneration to induce operational tolerance in the setting of half-size liver allogafts in rats, leaving the host and its immune system almost intact. Experimental Design And Grouping Teleologically our study is to establish the protocol for operational tolerance induction and make sure of its potentially clinical application. Reduced-size (50,70%) allograft LT was frequently performed clinically and used to trigger liver regeneration in our study. 30% liver graft is highly responsible for small-size syndrome and abolished in our study (see Methods). According to the references and our pilot study 16 , whole and 50% graft LT were performed to confirm the effect of liver regeneration of the smaller graft with once-a-day subcutaneous injection of cyclosporine A and recombinant human granulocyte stimulating factor(r-GSF)(see methods) 17 ; 50% graft LT was performed as the control only with the same immunosuppressant use to determine the effect of bone marrow stem cells (Table 1, Extended Data Table 1, Extended Data Fig. 1). The experiments are conducted in compliance with the standards and rules for animals set by the Institutional Animal Care Committee of Henan Provincial People’s Hospital. Combinations Graft N Treatment Survival (days) Lewis→BN (ctrl- group 1) 100% 5 CSA+ r-GSF 123,72,61,65,43 Lewis→BN (ctrl- group 2) 50% 6 CSA 163,97,157,89,68,59 Lewis→BN(tolerant group) 50% 12 CSA+ r-GSF 153,167,189,243,237,365,341 * ,113 * , 505,343,316,312 Table1 . Experimental grouping for graft size, treatment and survival. Cyclosporine A: CSA; recombinant human granulocyte stimulating factor: r-GSF;* for the death unrelated to rejection. For control groups, the hosts living over 2 weeks were included for survival analysis, the rats living more than 2 months were included for the tolerant group. Survivals, functions and structures of the rat liver allografts Clinically operational tolerance is defined as survival of an allograft without chronic rejection in the absence of any immunosuppression for more than 1 year (2 months for small animals). For the nonhuman organ transplantation, the graft survival is equivalent to the host life. In this study graft survival time was calculated from the day of transplantation to the time that chronic rejection was confirmed or the date of death correlated with rejection according to Banff criteria 18 . The core of operational tolerance is to assess whether the allograft's functions and structures are maintained normal after complete immunosuppression withdrawal. Liver allograft survival, functions and histological examinations were primary end-point foci. Glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) are conventional parameters to evaluate liver functions. Our result showed that the tolerant rats were freely living much longer than other rats in controls ( p =0.001, Fig.1). In 14 days post-LT, ALT and AST were gradually becoming normal in all groups; afterwards two values were maintained normal in the tolerant rats, much lower than those of 2 controls along with survival (Fig.2). Histology revealed that acute or chronic rejection developed within 2 months for the controls, and that the normal structures of liver grafts only with mild ductular reaction (scored 1) were detected in the tolerant rats, furthermore; sequential HE staining showed no fibrosis and no acute or chronic rejection in the tolerant rats, which were detected in controlled rats due to rejection (Fig.3,4, Extended Data Fig.2). Immunoglubin G was detected positive in the control groups (Fig.4, Extended Data Fig.2), CK19 as a biomarker of bile duct proliferation was stained more positive in the control rats than that in the tolerant rats (Fig.5, Extended Data Fig. 2). Liver allograft remodeling during liver regeneration To further gain insight into the underlying mechanism of liver regeneration in tolerance, we evaluated whether and how host-derived stem cells migrated, repopulated in the graft. 5-Bromo-2-deoxyuridine(Brdu)was used to evaluate liver regeneration, for the whole graft control group, liver regeneration almost discontinued; while it was relatively common in the tolerant grafts and the controlled half size allografts but much less frequent (Fig. 6 ). CD34 as a biomarker of bone marrow stem cells was used to evaluate whether host-derived stem cells migrated and repopulated after r-GSF mobilization. Immunohistochemistry showed that CD34 was most pronounced in the allograft of tolerant rats (Fig. 7 ), and that it was more pronounced in the control half size graft group than that of whole graft rats, indicating bone marrow stem cells repopulation was significant. CD133 was not detected in all allografts. Donor-specific Immune Response Lastly we perform skin transplantation to evaluate whether donor-specific immune hyporesponse occurs. Inbred donor strain skin transplantations were performed after 1 month post-LT. In animals of 3 groups, the skin allografts hardened and slough off in 2 weeks, robust immune reaction occurred to reject the skin allografts, indicating that naïve T cells failed to differentiate into memory T cells due to different spatial conformation of MHC molecules at the hypertrophy stage (Fig. 8 ). Discussion After LT, long-lasting calcineurin inhibitor-based multiple regimen with narrow therapeutic window is required exclusively to protect the graft against the host immune destruction, in the upper of this window, their cumulative side-effects and toxicities are possibly associated with infection, de novo malignancy and metabolic syndrome 19,20 , it was reported that approximately 80% of LT recipients were over-immunosuppressed 21 ; in the lower of this window, the allograft loss insidiously develops due to immune injury in the form of acute or chronic rejection. No optimized immunosuppression regimen is universally applicable. The side-effects and toxicities are the main roadblock of further improved outcomes of transplantation. Operational tolerance has emerged as the key strategy to further transplant outcomes. Clinically spontaneous tolerance was reported for the recipients several years after LT, under one-fourth recipients remained off immunosuppression use, especially pediatric LT recipients whose partial or reduced size grafts were used 12,22 . It was suggestive that the unique liver regeneration phenomenon was possibly the mechanism of tolerance. Sun et al confirmed that plerixafor-mobilized bone marrow stem cells reinstituted the graft to prolong survival in half size graft LT model from Dark-Agouti ( DA) to Lewis confirmed through Y chromosome track technique and the green fluorescent protein expression, it followed that CD133(not CD34) stem cells migrated and repopulated in the allograft. Their conclusion was self-perpetuating antigen specific immunosuppression rather than immune tolerance 23,24 . We speculated that half size DA liver graft underwent longer duration of regeneration because this rat is a poor metabolizer lacking cytochrome P450 subfamilies 25 , this model is the strongest rejection reaction resembling human LT, insufficient tacrolimus use (0.1mg/kg, totally four times in the first week) was the fundamental cause of chronic immune injury, resulting in compromised hepatocyte proliferation capacity, the small hepatocytes as one of hepatic progenitors started to proliferate, their study provided the clue as to that the injuries were ongoing in the allografts and liver regeneration or remodeling of the graft was taking place all the time. Our protocol offers the operational tolerance confirmed with histological examination completely in accordance to Banff criteria 18 . Why is the smaller liver allograft harbored well by the host on the synergistic effect of liver regeneration and bone marrow stem cells? The truths need to be elucidated. We propose that a series of events after half size graft implantation play roles of tolerance achievement in our study. One immediate outcome after smaller allograft implantation is channeling the entire portal blood flow through half vessels to increase portal blood pressure and provide initiating signals for liver regeneration 26 . On ischemia reperfusion injury, hepatocytes would first undergo growth or hypertrophy as compensation and their volume would increase by half in a few days which was evidenced and supported by less Brdu detection in the half size allograft of our study. At the hypertrophy stage, the dynamic and subtle variation of spatial conformation of MHC molecules changed the interaction between MHC and antigen peptides and led to the failure of the recognition of MHC molecule antigen peptide complexes by T cell receptor's exquisite docking 27.28 . Bone marrow stem cells mobilized commonly with r-GSF will migrate, repopulate and differentiate in the half size graft; mesenchymal stem cells are immunosuppressive by downregulating expression of costimulatory molecules, inhibiting differentiation of dendritic cells from CD34 progenitors and reducing proinflammatory cytokine secretion 29 , as a result, tissue repair is improved quickly, and the allograft was tolerated. It seems to be more in line with the Danger model 30 . After hypertrophy switches to hyperplasia, spatial conformation of MHC molecule is not restored to their original because of the exquisite specificity. The immune recognition does not occur. Hepatocyte proliferative capacity restores, small hepatocyte ' s specific biomarker CD44 were detected negative in tolerant rats, positive in control groups in our study 31 . In our study, operational tolerance was achieved in 100% of hosts, the allograft bespoke the almost completely normal microstructures over one year, hepatic infiltration in the tolerant rats was consistent with outcomes reported by Taubert et al and Todo et al but less mild than their results 9,31 . Of note, our protocol is of highly clinical relevance that it targets the allograft and interventions are easily operable and reproducible: reduced-size or split LT are extensively performed in many centers; the host-derived bone marrow stem cells are attainably interventional; the short-course and low dose immunosuppressant use confer little impact on the hosts, and overarching side-effects and toxicities associated with immunosuppression can be waived. In view of liver regeneration to induce tolerance, its proliferative index can be used as biomarkers to predict the tolerant state. In addition, the graft can be divided into parts which will be supplied to 2 recipients; the paradigm of one liver for two recipients will surely expand the donor pool to shorten the waitlist of LT. This operational tolerance was successfully induced in small animal, its procedures and intervention mimic human LT, nonhuman primate LT are warranted to expedite this protocol implicated in human LT. Online Content Any method, additional references, Nature research reporting summaries, source data, extended data, supplementary information, acknowledgements are available online. References 1. Ashok Jain, et al. Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center. Annals of Surgery 232.490-500 (2000). 2. A. Rana, et al. No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg 269, 20-27 (2019). 3. Paolo De Simone, et al. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol 31,199-209 (2017). 4. R. E. Billingham, L. Brent, P. B. Medawar, Actively acquired tolerance of foreign cells. Nature 172:603-606 (1953). 5. R.Y. Calne, et al. Induction of immunological tolerance by porcine liver allografts. Nature 223,472-476 (1969). 6. D. Houssin, et al. Specific transplantation tolerance induced by spontaneously tolerated liver allograft in inbred strains of rats. Transplantation 29,418-419 (1980). 7. Jessica Stolp, et al. Immune Tolerance and Rejection in Organ Transplantation. Methods Mol Biol 1899,159-180 (2019). 8. F.Cvetkovski, et al. Strategies for Liver Transplantation Tolerance. Int J Mol Sci 22(5):2253 (2021). 9. Satoru Todo, et al. Anti-Donor Regulatory T Cell Therapy in Liver Transplantation. Hum Immunol 79,288-293 (2018). 10. T.E. Starzl, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 17, 1127-1152 (1993). 11. X. Yan, et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. Transplantation 101, 1056-1066 (2017). 12. Sandy. Feng, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 307, 283-293 (2012). 13. P. Nagy, et al. Reconstitution of liver mass via cellular hypertrophy in the rat. Hepatology 33, 339-45(2001). 14. B. E. Petersen, et al. Bone marrow as a potential source of hepatic oval cells. Science 284,1168-1170 (1999). 15 F. P. Russo, et al .The Bone Marrow Functionally Contributes to Liver Fibrosis. Gastroenterology 130,1807-1821 (2006). 16. C. Kordes, et al. Hepatic stellate cells contribute to progenitor cells and liver regeneration. J. Clin. Invest 124, 5503-5515 (2014). 17. A. Shimizu, et al. Chronic Antibody-Mediated Responses May Mediate Chronic Rejection in Rat Orthotopic Liver Transplantation. Transplantation Proceedings 45, 1743-1747 (2013). 18. D.G. Ormonde, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg 5, 261-268 (1999). 19. R. Adam, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57,675-688 (2012). 20. SD. Johnston, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73,901-906 (2002). 21. M.C Londoño, et al. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. Journal of Hepatology 59, 872-879 (2013). 22. F. Oike, et al. Complete Withdrawal of Immunosuppression in Living Donor Liver Transplantation. Transplantation Proceedings 34, 1521 (2002). 23. Z.L. Sun, et al. Recruitment of Host Progenitor Cells in Rat Liver Transplants. Hepatology 49,587-597 (2009). 24. T. A. Okabayashi, et al. Mobilization of Host Stem Cells Enables Long-Term Liver Transplant Acceptance in a Strongly Rejecting Rat Strain Combination. American Journal of Transplantation 11, 2046-2056 (2011). 25. Y. Yamamoto, et al. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8,73-82 (1998). 26. George K Michalopoulos & Bharat Bhushan. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol 18:40-55 (2021). 27. Saeko. Yanaka, et al. Peptide-dependent Conformational Fluctuation Determines the Stability of the Human Leukocyte Antigen Class I omplex. J Biol Chem 289, 24680-24690 (2014). 28. Idit Matot, et al. Impaired liver regeneration after hepatectomy and bleeding is associated with a shift from hepatocyte proliferation to hypertrophy. FASEB J 31,5283-5295 (2017 ). 29. Polly Matzinger. The danger model: a renewed sense of self. Science 296, 301-305 (2002). 30.H. Fukasawa, et al. Morphological characterization of small hepatocytes after bile duct ligation in chicken. Poult. Sci 98,717-721 (2019). 31.R. Taubert, et al. Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated. American Journal of Transplantation 16, 1285-1293 (2016). methods Data reporting The sample size was predetermined according to the references without statistical methods 5,32,33 . The experiments were randomized and the investigators were blind during data analysis for all experiments. Rats Rats (200-300g weight) including Sprague Dawley (SD), Lewis, Brown Norway (BN), served as donors and recipients purchased from Beijing Vital River Laboratory Animal Technology Corporation. All animals were housed and cared in a temperature and light-controlled environment, freely access to food and bottle water, they were fasted 12 hours before LT. Orthotopic rat LT and experimental grouping Rat LT was performed by one surgeon. Under a modified mask for isoflurane inhalation anesthesia. Liver grafts were first perfused via the aorta with 5 ml of heparinized (50 U/mL) normal saline and then through the portal vein with 10 ml of cold lactated Ringer solution. The cold storage time was less than 3 hours. The recipient's native liver was explanted out and the allograft was orthotopically implanted, followed by the supra-hepatic vena cava anastomosis with a 8-0 running suture. The two-cuff technique was used for the reconnection of the portal vein and the infra-hepatic vena cava 34,35 . The arterial reconnection was made with a stent 36 . The biliary continuity was achieved by a polyethylene stent. The recipients were monitored daily for mobility, posture, weight, fur, skin and urination color. 50% LT graft consists of removal of left lateral lobe, removal of left portion of the middle lobe and caudate lobes; for 70% graft, only left lateral lobe is removed 37 . To make investigation of tolerance induction and the potential mechanism involved in liver regeneration, we performed OLT from Lewis to BN rat in the different groups, which is well-established model of strong acute rejection: whole graft LTs were performed to compare with half-size allograft LTs with daily subcutaneous injection of CSA at 2mg/kg for 9 days and r-GSF at 200u/kg for 5 days to study the significance of liver regeneration, half-size allograft LTs were performed only with same injection of CSA to emphasize the contribution of the host bone marrow stem cells into regenerating liver compared with tolerant group. 70% graft LTs were performed to compare with 50% graft LT for determination of graft size. Syngeneic graft LT was performed to provide the controls of histology images. Skin transplantation Inbred Lewis rats were used as skin donors and LT BN rats used as recipients. A 1.5 cm × 1.5 cm full thickness graft was prepared from the donor abdomen; A graft bed (1.5 cm × 1.5 cm) was prepared on the back of a recipient rat 38 . When the skin graft was attached to the back of the recipient with interrupted sutures of 5-0 silk. The graft was covered with a protective tape and the first inspection was done 3 days after skin grafting and daily thereafter. Rejection was defined as skin graft acquired a red–brown color, hard consistency and slough. Evaluation of liver regeneration 5-bromo-2'-deoxyuridine (BrdU) was injected intraperitoneally at 50mg/kg 24 hour before liver tissue harvest. The liver tissues were then cut into small pieces that were fixed in 10% neutral formalin, embedded in paraffin, and sectioned. BrdU-incorporated hepatocytes were detected by use of an immunochemical system18 for monitoring cell proliferation with a monoclonal anti-Brdu cell proliferation kit 39 (GB12051, Servicebio Inc. Wuhan, China). Blood collection and liver sample preparation When the subject rat was euthanatized, the rat's abdominal cavity was opened through the midline incision, the intestine was pulled out to expose the abdominal aorta, a blood collection needle was pierced into the aorta and connected to a negative air pressure tube containing EDTA for anti-coagulation, then the tube was upside down several times to prevent blood clotting. The plasma was gained at 2000g centrifuge for 10 minutes and aliquot was labeled and cryopreserved until use. According to spectrometry, the corresponding parameters were set on the automatic biochemical analyzer, the results were output after plasma is loaded. The liver allograft was perfused with normal saline through the mesenteric vein and extracted out. The graft was weighed and cut into several small parts, then immerged in 10% neutral paraformaldehyde solution for later use. Hematoxylin-eosin and i mmunohistochemistry staining Hematoxylin-eosin and masson staining were performed as conventionally described. Five-micrometer serially cut and frozen sections were fixed, the tissue section was placed in a retrieval box filled with citric acid (PH6.0) which was in a microwave oven for antigen retrieval to block endogenous peroxidase with 3% hydrogen peroxide solution. Then drop 3% BSA solution in the histochemical circle to cover the tissue evenly, and block for 30 minutes at room temperature. The primary antibodies were blocked with goat-derived rabbit serum, and other sources were blocked with BSA. The primary antibodies were added and incubated overnight. The secondary antibody (CD133) marked with HRP were added, whereas they were colored with DAB and controlled under microscope. Cell nucleus were counter-stained with hematoxylin. This procedures were applied to CD34,CD44,CK19 (Servicebio Inc. Wuhan, China) 24,40-43 . Statistics and reproducibility Statistical analysis was performed using IBM SPSS Statistic 22. Data availability All data generated and supporting the findings of this study are available within the paper, Additional information and materials will be made available including operation video upon request. 32. Y Shimizu , et al. Restoration of tolerance to rat hepatic allografts by spleen-derived passenger leukocytes. Transpl Int 9 ,593-595(1996). 33. Bettina Dresske, et al. Spontaneous Tolerance: Experience With the Rat Liver Transplant Model. Human Immunology 63 , 853-861 (2002). 34.Lee S, et al. A technique for orthotopic liver transplantation in the rat. Transplantation 16 ,664-669 (1973). 35.HB. Zhao, et al. Revisiting Orthotopic Rat Liver Transplant. Experimental and Clinical Transplantation 9 , 956-962 (2021). 36. ST. Zhou, et al. New method of stent-facilitated arterial reconstruction for orthotopic mouse liver transplantation. J Surg Res 18 7, 297-301(2014). 37. Nodir Madrahimov , et al. Marginal hepatectomy in the rat: from anatomy to surgery Ann Surg 244 ,89-98 (2006). 38. C. F. Barker & R. E. Billingham . Skeletal muscle as a privileged site for orthotopic skin allografts. J Exp Med 138 , 289-299 (1973). 39. N. Assy & G.Y. Minuk. Liver regeneration: Methods for monitoring and their applications. J Hepatol 26 , 945-952( 1997). 40. Evangelos Dalakas ,et al. Bone marrow stem cells contribute to alcohol liver fibrosis in humans. Stem Cells Dev 19 ,1417-1425 (2010). 41. S. J. Forbes, et al. A Significant Proportion of Myofibroblasts Are of Bone Marrow Origin in Human Liver Fibrosis. Gastroenterology 126 ,955-963(2004). 42. Y.H. Chen, et al. Contribution of Mature Hepatocytes to Small Hepatocyte-Like Progenitor Cells in Retrorsine-Exposed Rats With Chimeric Livers. Hepatology 57, 1215-1224 (2013). 43. R. Higashiyama, et al. Negligible Contribution of Bone Marrow-Derived Cells to Collagen Production During Hepatic Fibrogenesis in Mice. Gastroenterology 137 ,1459-1466 (2009). Declarations Acknowledgements This work was sponsored by Doctor initiative fund and project 23456 of Henan Provincial People’s Hospital. Authors' contributions ST. Z. conceived, designed, carried out, performed OLT, wrote manuscript and finalized the study. H.G. designed and performed the pathological examinations. GF.T. discussed the draft. H.B.Z. partly performed the experiments. SD.W. performed the analysis of data. XY.G animal caring. FZ.L. discussed the project. D.L. collected data. GY. C. funded and discussed the study. KD.C conceived and finalized the study. Additional Declarations There is NO Competing Interest. Supplementary Files 1researchhighlightsummary.docx research summary ExtendedData.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1505625","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":94852383,"identity":"4e4e0c36-653d-4b3a-81e1-30dde928c783","order_by":0,"name":"guoyong chen","email":"","orcid":"","institution":"Zhengzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"guoyong","middleName":"","lastName":"chen","suffix":""},{"id":94852384,"identity":"87eb3874-fbe2-4c6d-9306-7fd223676ff5","order_by":1,"name":"gaofeng Tang","email":"","orcid":"","institution":"Zhengzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"gaofeng","middleName":"","lastName":"Tang","suffix":""},{"id":94852385,"identity":"d09ae1e0-8aad-4182-8c22-2621e1db31e5","order_by":2,"name":"huibo zhao","email":"","orcid":"","institution":"Zhengzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"huibo","middleName":"","lastName":"zhao","suffix":""},{"id":94852386,"identity":"1bc39316-f302-4827-ac1c-37e3da49ce16","order_by":3,"name":"sidong wei","email":"","orcid":"","institution":"Zhengzhou University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"sidong","middleName":"","lastName":"wei","suffix":""},{"id":94852387,"identity":"5dc28c16-900e-4ab4-8dc8-f0d95e614a90","order_by":4,"name":"xiaoyan guo","email":"","orcid":"","institution":"Henan Academy of Traditional Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"xiaoyan","middleName":"","lastName":"guo","suffix":""},{"id":94852388,"identity":"93b97dee-760d-4640-b6e3-3573e3e00a55","order_by":5,"name":"fanhzhou liu","email":"","orcid":"","institution":"Henan Academy of Traditional Chinese Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"fanhzhou","middleName":"","lastName":"liu","suffix":""},{"id":94852389,"identity":"3a3499ee-6e5f-4bae-a5f6-b01f13586a91","order_by":6,"name":"Di lu","email":"","orcid":"","institution":"Henan Provincial People’s Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Di","middleName":"","lastName":"lu","suffix":""},{"id":94852390,"identity":"36d32548-b855-45b6-874a-22598d64ca5a","order_by":7,"name":"Hui Guo","email":"","orcid":"","institution":"Huazhong University of Science and Technology","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hui","middleName":"","lastName":"Guo","suffix":""},{"id":94852391,"identity":"580d7a4b-f7fd-4565-8fcd-9ff1cc68bcf9","order_by":8,"name":"shaotang zhou","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAuklEQVRIie3QsQrCMBCA4ZRAp9OuVyrURwgUuhjwQVwOCpn0DToUOji6FvRhKoGuzm59BMc6aXBzkKSbw/3DTfcNd0Jw3D+Gn/mCREo7ziAkV+kxNmoW0eoGawwS+bkd0ucUQ2FBKFHrnZdEl8FkQAClXfSjGMyh8RGJ+zIThI4sSUWN9ZPYkXQiBUULCoMIOIJABEqGEkRTbcD0gNY9mUJuybvqep90v01O1o6PWvvJdzRvneM4jvvVG4/BNLDLIYv2AAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-1391-3517","institution":"Zhengzhou University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"shaotang","middleName":"","lastName":"zhou","suffix":""}],"badges":[],"createdAt":"2022-03-30 13:05:36","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1505625/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1505625/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":19824200,"identity":"23f58999-18f9-4c90-a6dd-ee861164b30b","added_by":"auto","created_at":"2022-03-31 15:08:27","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":413194,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSurvival curves for 3 groups evaluated by Kaplan-Meier analysis\u003c/strong\u003e. \u0026nbsp;The deadline of survival time of all rats for this study was March.15 2022.\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/fb48c8cb1ebc633a6a50acc2.png"},{"id":19824893,"identity":"104f34c6-aa11-4a1d-bac1-59052db27c6c","added_by":"auto","created_at":"2022-03-31 15:18:27","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":199650,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eTrends for allograft liver functions with Stacked line chart.\u003c/strong\u003e ALT , AST for 3 groups, both peak in the early days, were gradually normal in about two weeks, afterward they were going down but higher in the control rats ,almost normal all the time only in the tolerant rats,.\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/f4c9c6b3cc3e982b82bfe9f6.jpeg"},{"id":19824894,"identity":"a8c9c327-854d-469c-b765-3f83e7e66d88","added_by":"auto","created_at":"2022-03-31 15:18:27","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":7888796,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHistology examinations of groups for different time.\u003c/strong\u003e The grafts were procured at end-point time (death or chronic rejection),a-c, whole graft control group (7,43,123 days), d-f, half size graft control group (6,59,157days). g-i, tolerant group (7d, 53d, 365days)\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/0d2867e3650de36f6af21615.png"},{"id":19824467,"identity":"99e7dc5f-7b76-4104-a614-068acbd37de7","added_by":"auto","created_at":"2022-03-31 15:13:27","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":6421303,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHistoimmunochemical staining for the structures of allograft of 3 groups. \u003c/strong\u003eCD3 for infiltrated lymphocytes, a (123d),b (157d), c (365d); IgG for immunoglobulin G deposit, d (65d),e (61d),f (341d); Masson, g (59d), h (68d), I (59d) and Vimentin staining for fibrosis, j (59d), k (157d), l (365d).\u0026nbsp;\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/4c61cc733cd7375aa0f02c5e.png"},{"id":19824469,"identity":"cea9ec29-655e-46c5-8802-9663e1c3ac89","added_by":"auto","created_at":"2022-03-31 15:13:27","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":7352605,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHistoimmunochemical staining for ductular reaction biomarker CK19. \u003c/strong\u003eCK19 was\u003cstrong\u003e \u003c/strong\u003emost remarkable in the whole graft group(a-c,6,43,123 d), also remarkable in the half-size graft control group(d-f, 7,59,157d), not remarkable in the tolerant rats(g-I, 7,54,365d)\u003c/p\u003e","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/3b3b49052ece2f71163f8b46.png"},{"id":19824204,"identity":"57913953-f075-4c53-be4a-e9025d978f33","added_by":"auto","created_at":"2022-03-31 15:08:27","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":7723017,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eLiver regeneration in the allografts of 3 groups evaluated by BrDu in different periods.\u003c/strong\u003e whole liver allograft showed almost no regeneration due to no injury (no signal), in the meantime, Brdu detection was more common in half-size allograft groups than that in the whole allograft(a-c,7,14,73d); after discontinued immunosuppression, immune injury developed insidiously in the whole liver allograft, on the contrary, Brdu was detected more commonly than that in the control half size rats (d-f, 6,14,157d) and the tolerant rats (g-i,7, 13, 365d ).\u003c/p\u003e","description":"","filename":"floatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/a935bf0ed70f9ec04898c221.png"},{"id":19824207,"identity":"af6de95a-64f0-4dd2-bedb-83607091deef","added_by":"auto","created_at":"2022-03-31 15:08:27","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":7520356,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePeri-operatively histoimmunochemical staining for bone marrow stem cells with biomarkers of CD34, CD133.\u003c/strong\u003e CD34 was most remarkable in the tolerant rats, more in the half-size graft of the control groups, less in the whole graft group. a(6 d),b(7d),c(7d).CD133 was negative in 3 groups, d(6d),e(7d),f(7d).CD44 stands for small hepatocytes. g (59 d),h (68d),I (341d).\u003c/p\u003e","description":"","filename":"floatimage7.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/a760bc4efff6aa1767ff4375.png"},{"id":19824209,"identity":"86d39173-d032-4983-92dd-7bf46aba311e","added_by":"auto","created_at":"2022-03-31 15:08:28","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":6585454,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSkin transplantation for 3 groups. \u003c/strong\u003eDonor skin grafts started to harden 4 days after operation and sloughed off in 14 days in 3 groups, indicating strong rejection occurrence.\u0026nbsp;\u003c/p\u003e","description":"","filename":"floatimage8.png","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/5b406c6352cf2dab9b224fad.png"},{"id":19824896,"identity":"ee82bb7a-6105-42c6-84a7-9880478455e5","added_by":"auto","created_at":"2022-03-31 15:18:31","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3893368,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/c9a666ef-ca8a-4c65-847d-6ba9ea78f7ce.pdf"},{"id":19824201,"identity":"ef1a72c4-58be-465b-8ae6-005d67721560","added_by":"auto","created_at":"2022-03-31 15:08:27","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":19498,"visible":true,"origin":"","legend":"research summary","description":"","filename":"1researchhighlightsummary.docx","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/3abf6383951dcddb389a9981.docx"},{"id":19824202,"identity":"be3676e4-05a5-4d24-bfde-28cb8a23ca2d","added_by":"auto","created_at":"2022-03-31 15:08:27","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":3849497,"visible":true,"origin":"","legend":"","description":"","filename":"ExtendedData.docx","url":"https://assets-eu.researchsquare.com/files/rs-1505625/v1/62b890bb1785290b40d24b61.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"The host bone marrow stem cell repopulation is crucial to the permanent tolerance in 50% liver transplantation","fulltext":[{"header":"Introduction","content":"\u003cp\u003eLiver transplantation (LT) is well accepted as the only life-saving treatment for benign end-stage liver diseases, metabolic liver diseases and liver tumors. Chronic immunosuppression is standard-of-care to preserve the donor allografts, bringing about the disreputably adverse effects associated with systemic toxicities, lower quality of life and greater cost burden\u003csup\u003e1\u0026ndash;3\u003c/sup\u003e. It was reported that the recipients had hardly gained longer-term survival post- LT for decades\u003csup\u003e2\u003c/sup\u003e. Operational tolerance can overcome major histocompatibility complex (MHC) barriers and permit complete withdrawal of immunosuppressants; it holds a promise as the Holy Grail. Peter Medawar first realized skin graft tolerance using fetal mice with immature immunology to make transplant a reality\u003csup\u003e4\u003c/sup\u003e. Calne et al reported spontaneous tolerance induction using the liver allograft heterotopically placed in pigs\u003csup\u003e5\u003c/sup\u003e. Later Houssin et al also successfully induced tolerance using an accessory semi-allograft in rats while the host total liver removal was performed after the graft implantation to spontaneously accept other grafts like the heart and skin from the same donor, demonstrating that the liver is immunologically privileged\u003csup\u003e6\u003c/sup\u003e. Both protocols did not mimic clinical practice. Great immunology progresses have advanced our understanding of rejection as a bi-directional immune activity in nature between the host and the graft. All strategies of tolerance induction targeted the host and immune reaction, deletion or anergy of T cells, blockade of costimulatory signals and adoptive transfer of regulatory T cells were designed and carried out\u003csup\u003e7,8,\u003c/sup\u003e, these proof-of-principle studies cannot be extrapolated to the clinic. Starzl pioneered human LT and pinpointed out chimerism was the frequent state of the long-living recipients\u003csup\u003e9\u003c/sup\u003e. Currently it is documented that macrochimerism achieved by hematopoietic cell transplantation from the solid organ donor is essential to operational tolerance, but maintaining macrochimerism is challenging due to continuous immune deletion or destruction by the host over time, and hematopoietic cell transplantation will incur life-threatening complications like severe infections and graft versus host disease\u003csup\u003e10,11\u003c/sup\u003e, it is noted that clinical trials for this protocol are under way.\u003c/p\u003e \u003cp\u003eFeng et al reported a higher rate of spontaneous tolerance of parental partial allograft in highly selective pediatric recipients, suggesting that liver regeneration was possibly attributable to tolerance\u003csup\u003e12\u003c/sup\u003e. The liver has a unique regenerative capacity to restore his native mass following major resection, this unique phenomenon like an elephant in the room is neglected in tolerance induction. Liver regeneration exists in three forms or sources: hepatocytes (accounting for 80% of parenchyma cells), liver-resident progenitors (\u0026lt;\u0026thinsp;2%) and extra-hepatic stem cells. Generally, the basic premise of hepatocyte proliferation is the intact hepatocytes upon hepatectomy; when intra-hepatic cell proliferation was refrained, extra-hepatic progenitors contributed to this process\u003csup\u003e13\u0026ndash;15\u003c/sup\u003e. Here we deployed unique liver regeneration to induce operational tolerance in the setting of half-size liver allogafts in rats, leaving the host and its immune system almost intact.\u003c/p\u003e"},{"header":"Experimental Design And Grouping","content":"\u003cp\u003eTeleologically our study is to establish the protocol for operational tolerance induction and make sure of its potentially clinical application. Reduced-size (50,70%) allograft LT was frequently performed clinically and used to trigger liver regeneration in our study. 30% liver graft is highly responsible for small-size syndrome and abolished in our study (see Methods). According to the references and our pilot study\u003csup\u003e16\u003c/sup\u003e, whole and 50% graft LT were performed to confirm the effect of liver regeneration of the smaller graft with once-a-day subcutaneous injection of cyclosporine A and recombinant human granulocyte stimulating factor(r-GSF)(see methods)\u003csup\u003e17\u003c/sup\u003e; 50% graft LT was performed as the control only with the same immunosuppressant use to determine the effect of bone marrow stem cells (Table 1, Extended Data Table 1,\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eExtended Data Fig. 1). The experiments are conducted in compliance with the standards and rules for animals set by the Institutional Animal Care Committee of Henan Provincial People\u0026rsquo;s Hospital. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003ctable style=\"width:459.0pt;border-collapse:collapse;border:none;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 459pt;border: 1pt solid windowtext;padding: 0in 5.4pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:19px;font-family:\"Calibri\",sans-serif;margin-right:-7.0pt;'\u003e\u003cstrong\u003e\u0026nbsp; \u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u003cspan style='font-size:12px;font-family: \"Times New Roman\",serif;'\u003eCombinations \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Graft \u0026nbsp; \u0026nbsp; \u0026nbsp; N \u0026nbsp; \u0026nbsp; Treatment \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Survival \u0026nbsp;(days)\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 459pt;border-color: currentcolor windowtext windowtext;border-style: none solid solid;border-width: medium 1pt 1pt;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 47.8pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:19px;font-family:\"Calibri\",sans-serif;margin-right:-7.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;'\u003eLewis\u0026rarr;BN (ctrl- group 1) \u0026nbsp; \u0026nbsp;100% \u0026nbsp; \u0026nbsp; \u0026nbsp;5 \u0026nbsp; \u0026nbsp; CSA+ r-GSF \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 123,72,61,65,43\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:19px;font-family:\"Calibri\",sans-serif;margin-right:-7.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;'\u003eLewis\u0026rarr;BN (ctrl- group 2) \u0026nbsp; \u0026nbsp;50% \u0026nbsp; \u0026nbsp; \u0026nbsp; 6 \u0026nbsp; \u0026nbsp; CSA \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;163,97,157,89,68,59\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:19px;font-family:\"Calibri\",sans-serif;margin-right:-7.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;'\u003eLewis\u0026rarr;BN(tolerant group) \u0026nbsp; 50% \u0026nbsp; \u0026nbsp; \u0026nbsp;12 \u0026nbsp; \u0026nbsp; CSA+ r-GSF \u0026nbsp; \u0026nbsp; \u0026nbsp; 153,167,189,243,237,365,341\u003c/span\u003e\u003cspan style='font-size:14px;font-family:\"Times New Roman\",serif;'\u003e*\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;'\u003e,113\u003c/span\u003e\u003cspan style='font-size:14px;font-family:\"Times New Roman\",serif;'\u003e*\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;'\u003e,\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e505,343,316,312\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:19px;font-family:\"Calibri\",sans-serif;line-height:200%;'\u003e\u003cstrong\u003e\u003cspan style='font-size: 14px; line-height: 200%; font-family: \"Times New Roman\", serif; color: rgb(0, 0, 0);'\u003eTable1\u003c/span\u003e\u003c/strong\u003e\u003cspan style='font-size: 14px; line-height: 200%; font-family: \"Times New Roman\", serif; color: rgb(0, 0, 0);'\u003e.\u003cstrong\u003e\u0026nbsp;Experimental grouping for graft size, treatment and survival.\u003c/strong\u003e Cyclosporine A: CSA;\u003c/span\u003e\u003cspan style=\"color: rgb(0, 0, 0);\"\u003e\u0026nbsp;\u003c/span\u003e\u003cspan style='font-size: 14px; line-height: 200%; font-family: \"Times New Roman\", serif; color: rgb(0, 0, 0);'\u003erecombinant human granulocyte stimulating factor: r-GSF;* for the death unrelated to rejection. For control groups, the hosts living over 2 weeks were included for survival analysis, the rats living more than 2 months were included for the tolerant group.\u003c/span\u003e\u003c/p\u003e"},{"header":"Survivals, functions and structures of the rat liver allografts","content":"\u003cp\u003eClinically operational tolerance is defined as survival of an allograft without chronic rejection in the absence of any immunosuppression for more than 1 year (2 months for small animals). For the nonhuman organ transplantation, the graft survival is equivalent to the host life. In this study graft survival time was calculated from the day of transplantation to the time that chronic rejection was confirmed or the date of death correlated with rejection according to Banff criteria\u003csup\u003e18\u003c/sup\u003e. The core of operational tolerance is to assess whether the allograft\u0026apos;s functions and structures are maintained normal after complete immunosuppression withdrawal. Liver allograft survival, functions and histological examinations were primary end-point foci. Glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) are conventional parameters to evaluate liver functions. Our result showed that the tolerant rats were freely living much longer than other rats in controls (\u003cem\u003ep\u003c/em\u003e=0.001, Fig.1). In 14 days post-LT, ALT and AST were gradually becoming normal in all groups; afterwards two values were maintained normal in the tolerant rats, much lower than those of 2 controls along with survival (Fig.2). Histology revealed that acute or chronic rejection developed within 2 months for the controls, and that the normal structures of liver grafts only with mild ductular reaction (scored 1) were detected in the tolerant rats, furthermore; sequential HE staining showed no fibrosis and no acute or chronic rejection in the tolerant rats, which were detected in controlled rats due to rejection (Fig.3,4, Extended Data Fig.2). Immunoglubin G was detected positive in the control groups (Fig.4, Extended Data Fig.2), CK19 as a biomarker of bile duct proliferation was stained more positive in the control rats than that in the tolerant rats (Fig.5,\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eExtended Data Fig. 2).\u003c/p\u003e"},{"header":"Liver allograft remodeling during liver regeneration","content":"\u003cp\u003eTo further gain insight into the underlying mechanism of liver regeneration in tolerance, we evaluated whether and how host-derived stem cells migrated, repopulated in the graft. 5-Bromo-2-deoxyuridine(Brdu)was used to evaluate liver regeneration, for the whole graft control group, liver regeneration almost discontinued; while it was relatively common in the tolerant grafts and the controlled half size allografts but much less frequent (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e). CD34 as a biomarker of bone marrow stem cells was used to evaluate whether host-derived stem cells migrated and repopulated after r-GSF mobilization. Immunohistochemistry showed that CD34 was most pronounced in the allograft of tolerant rats (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003e), and that it was more pronounced in the control half size graft group than that of whole graft rats, indicating bone marrow stem cells repopulation was significant. CD133 was not detected in all allografts.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Donor-specific Immune Response","content":"\u003cp\u003eLastly we perform skin transplantation to evaluate whether donor-specific immune hyporesponse occurs. Inbred donor strain skin transplantations were performed after 1 month post-LT. In animals of 3 groups, the skin allografts hardened and slough off in 2 weeks, robust immune reaction occurred to reject the skin allografts, indicating that na\u0026iuml;ve T cells failed to differentiate into memory T cells due to different spatial conformation of MHC molecules at the hypertrophy stage (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eAfter LT, long-lasting calcineurin inhibitor-based multiple regimen with narrow therapeutic window is required exclusively to protect the graft against the host immune destruction, in the upper of this window, their cumulative side-effects and\u003c/p\u003e \u003cp\u003etoxicities are possibly associated with infection, de novo malignancy and metabolic syndrome\u003csup\u003e19,20\u003c/sup\u003e, it was reported that approximately 80% of LT recipients were over-immunosuppressed\u003csup\u003e21\u003c/sup\u003e; in the lower of this window, the allograft loss insidiously develops due to immune injury in the form of acute or chronic rejection. No optimized immunosuppression regimen is universally applicable. The side-effects and toxicities are the main roadblock of further improved outcomes of transplantation. Operational tolerance has emerged as the key strategy to further transplant outcomes.\u003c/p\u003e \u003cp\u003eClinically spontaneous tolerance was reported for the recipients several years after LT, under one-fourth recipients remained off immunosuppression use, especially pediatric LT recipients whose partial or reduced size grafts were used\u003csup\u003e12,22\u003c/sup\u003e. It was suggestive that the unique liver regeneration phenomenon was possibly the mechanism of tolerance. Sun et al confirmed that plerixafor-mobilized bone marrow stem cells reinstituted the graft to prolong survival in half size graft LT model from Dark-Agouti \u003cb\u003e(\u003c/b\u003eDA) to Lewis confirmed through Y chromosome track technique and the green fluorescent protein expression, it followed that CD133(not CD34) stem cells migrated and repopulated in the allograft. Their conclusion was self-perpetuating antigen specific immunosuppression rather than immune tolerance\u003csup\u003e23,24\u003c/sup\u003e. We speculated that half size DA liver graft underwent longer duration of regeneration because this rat is a poor metabolizer lacking cytochrome P450 subfamilies\u003csup\u003e25\u003c/sup\u003e, this model is the strongest rejection reaction resembling human LT, insufficient tacrolimus use (0.1mg/kg, totally four times in the first week) was the fundamental cause of chronic immune injury, resulting in compromised hepatocyte proliferation capacity, the small hepatocytes as one of hepatic progenitors started to proliferate, their study provided the clue as to that the injuries were ongoing in the allografts and liver regeneration or remodeling of the graft was taking place all the time.\u003c/p\u003e \u003cp\u003eOur protocol offers the operational tolerance confirmed with histological examination completely in accordance to Banff criteria\u003csup\u003e18\u003c/sup\u003e. Why is the smaller liver allograft harbored well by the host on the synergistic effect of liver regeneration and bone marrow stem cells? The truths need to be elucidated. We propose that a series of events after half size graft implantation play roles of tolerance achievement in our study. One immediate outcome after smaller allograft implantation is channeling the entire portal blood flow through half vessels to increase portal blood pressure and provide initiating signals for liver regeneration\u003csup\u003e26\u003c/sup\u003e. On ischemia reperfusion injury, hepatocytes would first undergo growth or hypertrophy as compensation and their volume would increase by half in a few days which was evidenced and supported by less Brdu detection in the half size allograft of our study. At the hypertrophy stage, the dynamic and subtle variation of spatial conformation of MHC molecules changed the interaction between MHC and antigen peptides and led to the failure of the recognition of MHC molecule antigen peptide complexes by T cell receptor's exquisite docking \u003csup\u003e27.28\u003c/sup\u003e. Bone marrow stem cells mobilized commonly with r-GSF will migrate, repopulate and differentiate in the half size graft; mesenchymal stem cells are immunosuppressive by downregulating expression of costimulatory molecules, inhibiting differentiation of dendritic cells from CD34 progenitors and reducing proinflammatory cytokine secretion\u003csup\u003e29\u003c/sup\u003e, as a result, tissue repair is improved quickly, and the allograft was tolerated. It seems to be more in line with the Danger model\u003csup\u003e30\u003c/sup\u003e. After hypertrophy switches to hyperplasia, spatial conformation of MHC molecule is not restored to their original because of the exquisite specificity. The immune recognition does not occur. Hepatocyte proliferative capacity restores, small hepatocyte\u003csup\u003e'\u003c/sup\u003es specific biomarker CD44 were detected negative in tolerant rats, positive in control groups in our study\u003csup\u003e31\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn our study, operational tolerance was achieved in 100% of hosts, the allograft bespoke the almost completely normal microstructures over one year, hepatic infiltration in the tolerant rats was consistent with outcomes reported by Taubert et al and Todo et al but less mild than their results\u003csup\u003e9,31\u003c/sup\u003e. Of note, our protocol is of highly clinical relevance that it targets the allograft and interventions are easily operable and reproducible: reduced-size or split LT are extensively performed in many centers; the host-derived bone marrow stem cells are attainably interventional; the short-course and low dose immunosuppressant use confer little impact on the hosts, and overarching side-effects and toxicities associated with immunosuppression can be waived. In view of liver regeneration to induce tolerance, its proliferative index can be used as biomarkers to predict the tolerant state. In addition, the graft can be divided into parts which will be supplied to 2 recipients; the paradigm of one liver for two recipients will surely expand the donor pool to shorten the waitlist of LT.\u003c/p\u003e \u003cp\u003eThis operational tolerance was successfully induced in small animal, its procedures and intervention mimic human LT, nonhuman primate LT are warranted to expedite this protocol implicated in human LT.\u003c/p\u003e"},{"header":"Online Content","content":"\u003cp\u003eAny method, additional references, Nature research reporting summaries, source data, extended data, supplementary information, acknowledgements are available online.\u003c/p\u003e"},{"header":"References","content":"\u003cp\u003e1.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Ashok Jain, et al. Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center. Annals of Surgery 232.490-500 (2000).\u003c/p\u003e\n\u003cp\u003e2.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;A. Rana, et al. No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg 269, 20-27 (2019).\u003c/p\u003e\n\u003cp\u003e3.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Paolo De Simone, et al. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol 31,199-209 (2017).\u003c/p\u003e\n\u003cp\u003e4.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;R. E. Billingham, L. Brent, P. B. Medawar, Actively acquired tolerance of foreign cells. Nature 172:603-606 (1953).\u003c/p\u003e\n\u003cp\u003e5. R.Y. Calne, et al. Induction of immunological tolerance by porcine liver allografts. Nature 223,472-476 (1969).\u003c/p\u003e\n\u003cp\u003e6. D. Houssin, et al. Specific transplantation tolerance induced by spontaneously tolerated liver allograft in inbred strains of rats. Transplantation 29,418-419 (1980).\u003c/p\u003e\n\u003cp\u003e7. Jessica Stolp, et al. Immune Tolerance and Rejection in Organ Transplantation. Methods Mol Biol 1899,159-180 (2019).\u003c/p\u003e\n\u003cp\u003e8. F.Cvetkovski, et al. Strategies for Liver Transplantation Tolerance. Int J Mol Sci 22(5):2253 (2021).\u003c/p\u003e\n\u003cp\u003e9. Satoru Todo, et al. Anti-Donor Regulatory T Cell Therapy in Liver Transplantation. Hum Immunol 79,288-293 (2018).\u003c/p\u003e\n\u003cp\u003e10. T.E. Starzl, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 17, 1127-1152 (1993).\u003c/p\u003e\n\u003cp\u003e11. X. Yan, et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. Transplantation 101, 1056-1066 (2017).\u003c/p\u003e\n\u003cp\u003e12. Sandy. Feng, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 307, 283-293 (2012).\u003c/p\u003e\n\u003cp\u003e13. P. Nagy, et al. Reconstitution of liver mass via cellular hypertrophy in the rat. Hepatology 33, 339-45(2001).\u003c/p\u003e\n\u003cp\u003e14. B. E. Petersen, et al. Bone marrow as a potential source of hepatic oval cells. Science 284,1168-1170 (1999).\u003c/p\u003e\n\u003cp\u003e15 F. P. Russo, et al .The Bone Marrow Functionally Contributes to Liver Fibrosis. Gastroenterology 130,1807-1821 (2006).\u003c/p\u003e\n\u003cp\u003e16. C. Kordes, et al. Hepatic stellate cells contribute to progenitor cells and liver regeneration. J. Clin. Invest 124, 5503-5515 (2014).\u003c/p\u003e\n\u003cp\u003e17. A. Shimizu, et al. Chronic Antibody-Mediated Responses May Mediate Chronic Rejection in Rat Orthotopic Liver Transplantation. Transplantation Proceedings 45, 1743-1747 (2013).\u003c/p\u003e\n\u003cp\u003e18. D.G. Ormonde, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg 5, 261-268 (1999).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;19. R. Adam, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57,675-688 (2012).\u003c/p\u003e\n\u003cp\u003e20. SD. Johnston, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73,901-906 (2002).\u003c/p\u003e\n\u003cp\u003e21. M.C Londo\u0026ntilde;o, et al. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. Journal of Hepatology 59, 872-879 (2013).\u003c/p\u003e\n\u003cp\u003e22. F. Oike, et al. Complete Withdrawal of Immunosuppression in Living Donor Liver Transplantation. Transplantation Proceedings 34, 1521 (2002).\u003c/p\u003e\n\u003cp\u003e23. Z.L. Sun, et al. Recruitment of Host Progenitor Cells in Rat Liver Transplants. Hepatology 49,587-597 (2009).\u003c/p\u003e\n\u003cp\u003e24. T. A. Okabayashi, et al. Mobilization of Host Stem Cells Enables Long-Term Liver Transplant Acceptance in a Strongly Rejecting Rat Strain Combination. American Journal of Transplantation 11, 2046-2056 (2011).\u003c/p\u003e\n\u003cp\u003e25. Y. Yamamoto, et al. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8,73-82 (1998).\u003c/p\u003e\n\u003cp\u003e26. George K Michalopoulos \u0026amp; Bharat Bhushan. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol 18:40-55 (2021).\u003c/p\u003e\n\u003cp\u003e27. Saeko. Yanaka, et al. Peptide-dependent Conformational Fluctuation Determines the Stability of the Human Leukocyte Antigen Class I omplex. J Biol Chem 289, 24680-24690 (2014).\u003c/p\u003e\n\u003cp\u003e28. Idit Matot, et al. Impaired liver regeneration after hepatectomy and bleeding is associated with a shift from hepatocyte proliferation to hypertrophy. FASEB J 31,5283-5295 (2017 ).\u003c/p\u003e\n\u003cp\u003e29. Polly Matzinger. The danger model: a renewed sense of self. Science 296, 301-305 (2002).\u003c/p\u003e\n\u003cp\u003e30.H. Fukasawa, et al. Morphological characterization of small hepatocytes after bile duct ligation in chicken. Poult. Sci 98,717-721 (2019).\u003c/p\u003e\n\u003cp\u003e31.R. Taubert, et al. Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated. American Journal of Transplantation 16, 1285-1293 (2016).\u003c/p\u003e"},{"header":"methods","content":"\u003cp\u003e\u003cstrong\u003eData reporting\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe sample size was predetermined according to the references without statistical methods\u003csup\u003e5,32,33\u003c/sup\u003e. The experiments were randomized and the investigators were blind during data analysis for all experiments.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRats\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRats\u0026nbsp;(200-300g\u0026nbsp;weight)\u0026nbsp;including Sprague Dawley (SD), Lewis,\u0026nbsp;Brown Norway (BN),\u0026nbsp;served\u0026nbsp;as donors and recipients purchased from Beijing Vital River Laboratory Animal Technology Corporation. All animals were\u0026nbsp;housed\u0026nbsp;and cared\u0026nbsp;in a temperature and light-controlled environment, freely access to food and bottle water, they were fasted 12 hours\u0026nbsp;before LT.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrthotopic rat LT and experimental grouping\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRat LT was performed by one surgeon. Under a modified mask for isoflurane inhalation anesthesia. Liver grafts were first perfused via the aorta with 5 ml of heparinized (50 U/mL) normal saline and then through the portal vein with 10 ml of cold lactated Ringer solution. The cold storage time was less than 3 hours. The recipient\u0026apos;s native liver was explanted out and the allograft was orthotopically implanted, followed by the supra-hepatic vena cava anastomosis with a 8-0 running suture. The two-cuff technique was used for the reconnection of the portal vein and the infra-hepatic vena cava\u003csup\u003e34,35\u003c/sup\u003e. The arterial reconnection was made with a stent\u003csup\u003e36\u003c/sup\u003e. The biliary continuity was achieved by a polyethylene stent. The recipients were monitored daily for mobility, posture, weight, fur, skin and urination color. 50% LT graft consists of removal of left lateral lobe, removal of left portion of the middle lobe and caudate lobes; for 70% graft, only left lateral lobe is removed\u003csup\u003e37\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eTo make investigation of tolerance induction and the potential mechanism involved in liver regeneration, we performed OLT from Lewis to BN rat in the different groups, which is well-established model of strong acute rejection: whole graft LTs were performed to compare with half-size allograft LTs with daily subcutaneous injection of CSA at 2mg/kg for 9 days and r-GSF at 200u/kg for 5 days to study the significance of liver regeneration, half-size allograft LTs were performed only with same injection of CSA to emphasize the contribution of the host bone marrow stem cells into regenerating liver compared with tolerant group. 70% graft LTs were performed to compare with 50% graft LT for determination of graft size. Syngeneic graft LT was performed to provide the controls of histology images.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSkin transplantation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInbred Lewis rats were used as skin donors and LT BN rats used as recipients. A 1.5 cm \u0026times; 1.5 cm full thickness graft was prepared from the donor abdomen; A graft bed (1.5 cm \u0026times; 1.5 cm) was prepared on the back of a recipient rat\u003csup\u003e38\u003c/sup\u003e. When the skin graft was attached to the back of the recipient with interrupted sutures of 5-0 silk. The graft was covered with a protective tape and the first inspection was done 3 days after skin grafting and daily thereafter. Rejection was defined as skin graft acquired a red\u0026ndash;brown color, hard consistency and slough.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvaluation of liver regeneration\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e5-bromo-2\u0026apos;-deoxyuridine (BrdU) was injected intraperitoneally at 50mg/kg 24 hour before liver tissue harvest.\u0026nbsp;The liver tissues were then cut into small pieces that were fixed in 10% neutral formalin, embedded in paraffin, and sectioned. BrdU-incorporated hepatocytes were detected by use of an immunochemical system18 for monitoring cell proliferation with a monoclonal anti-Brdu cell proliferation kit\u003csup\u003e39\u003c/sup\u003e (GB12051, Servicebio Inc. Wuhan, China).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eBlood collection and liver sample preparation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhen the subject rat was euthanatized, the rat\u0026apos;s abdominal cavity was opened through the midline incision, the intestine was pulled out to expose the abdominal aorta, a blood collection needle was pierced into the aorta and connected to a negative air pressure tube containing EDTA for anti-coagulation, then the tube was upside down several times to prevent blood clotting. The plasma was gained at 2000g centrifuge for 10 minutes and aliquot was labeled and cryopreserved until use. According to spectrometry, the corresponding parameters were set on the automatic biochemical analyzer, \u0026nbsp;the results were output after plasma is loaded.\u003c/p\u003e\n\u003cp\u003eThe liver allograft was perfused with normal saline through the mesenteric vein and extracted out. The graft was weighed and cut into several small parts, then immerged in 10% neutral paraformaldehyde solution for later use.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHematoxylin-eosin and i\u003c/strong\u003e\u003cstrong\u003emmunohistochemistry\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;staining\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHematoxylin-eosin and masson staining were performed as conventionally described. Five-micrometer serially cut and frozen sections were fixed,\u0026nbsp;the tissue section was placed in a retrieval box filled with citric acid (PH6.0) which was in a microwave oven for antigen retrieval to block endogenous peroxidase with 3% hydrogen peroxide solution. Then drop 3% BSA solution in the histochemical circle to cover the tissue evenly, and block for 30 minutes at room temperature. The primary antibodies were blocked with goat-derived rabbit serum, and other sources were blocked with BSA. The primary antibodies were added and incubated overnight. The secondary antibody (CD133) marked with HRP were added, whereas they were colored with DAB and controlled under microscope. Cell nucleus were counter-stained with hematoxylin. This procedures were applied to CD34,CD44,CK19\u0026nbsp;(Servicebio Inc. Wuhan, China)\u003csup\u003e24,40-43\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistics and reproducibility\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStatistical analysis was performed using IBM SPSS Statistic 22.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data generated and supporting the findings of this study are available within the paper,\u0026nbsp;Additional information and materials will be made available including operation video upon request.\u003c/p\u003e\n\u003cp\u003e32.\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/?term=Shimizu+Y\u0026cauthor_id=8914241\"\u003eY Shimizu\u003c/a\u003e, et al. Restoration of tolerance to rat hepatic allografts by spleen-derived passenger leukocytes. Transpl Int \u003cstrong\u003e9\u003c/strong\u003e,593-595(1996).\u003c/p\u003e\n\u003cp\u003e33. Bettina Dresske, et al. Spontaneous Tolerance: Experience With the Rat Liver Transplant Model. Human Immunology\u003cstrong\u003e\u0026nbsp;63\u003c/strong\u003e, 853-861 (2002).\u003c/p\u003e\n\u003cp\u003e34.Lee S, et al. A technique for orthotopic liver transplantation in the rat. Transplantation \u003cstrong\u003e16\u003c/strong\u003e,664-669 (1973).\u003c/p\u003e\n\u003cp\u003e35.HB. Zhao, et al. Revisiting Orthotopic Rat Liver Transplant.\u003cstrong\u003e\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eExperimental and Clinical Transplantation \u003cstrong\u003e9\u003c/strong\u003e, 956-962 (2021).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e36. ST. Zhou, et al. New method of stent-facilitated arterial reconstruction for orthotopic mouse liver transplantation. J Surg Res \u003cstrong\u003e18\u003c/strong\u003e7, 297-301(2014).\u003c/p\u003e\n\u003cp\u003e37. \u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/?term=Madrahimov+N\u0026cauthor_id=16794393\"\u003eNodir Madrahimov\u003c/a\u003e, et al. Marginal hepatectomy in the rat: from anatomy to surgery Ann Surg \u003cstrong\u003e244\u003c/strong\u003e,89-98 (2006).\u003c/p\u003e\n\u003cp\u003e38.\u0026nbsp;\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/?term=Barker+CF\u0026cauthor_id=4577620\"\u003eC. F. Barker\u003c/a\u003e\u0026amp;\u0026nbsp;\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/?term=Billingham+RE\u0026cauthor_id=4577620\"\u003eR. E. Billingham\u003c/a\u003e. Skeletal muscle as a privileged site for orthotopic skin allografts. J Exp Med \u003cstrong\u003e138\u003c/strong\u003e, 289-299 (1973).\u003c/p\u003e\n\u003cp\u003e39. N. Assy \u0026amp; G.Y. Minuk. Liver regeneration: Methods for monitoring and \u0026nbsp;their applications. J Hepatol \u003cstrong\u003e26\u003c/strong\u003e, 945-952( 1997).\u003c/p\u003e\n\u003cp\u003e40.\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/?term=Dalakas+E\u0026cauthor_id=20025456\"\u003eEvangelos Dalakas\u003c/a\u003e,et al. Bone marrow stem cells contribute to alcohol liver fibrosis in humans. Stem Cells Dev \u003cstrong\u003e19\u003c/strong\u003e,1417-1425 (2010).\u003c/p\u003e\n\u003cp\u003e41. S. J. Forbes, et al. A Significant Proportion of Myofibroblasts Are of Bone Marrow Origin in Human Liver Fibrosis. Gastroenterology\u003cstrong\u003e126\u003c/strong\u003e,955-963(2004).\u003c/p\u003e\n\u003cp\u003e42. Y.H. Chen, et al. Contribution of Mature Hepatocytes to Small Hepatocyte-Like Progenitor Cells in Retrorsine-Exposed Rats With Chimeric Livers. Hepatology \u003cstrong\u003e57,\u003c/strong\u003e1215-1224 (2013).\u003c/p\u003e\n\u003cp\u003e43. R. Higashiyama, et al. Negligible Contribution of Bone Marrow-Derived Cells to Collagen Production During Hepatic Fibrogenesis in Mice. Gastroenterology \u003cstrong\u003e137\u003c/strong\u003e,1459-1466 (2009).\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was sponsored by Doctor initiative fund and project 23456 of Henan Provincial People\u0026rsquo;s Hospital.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eST. Z. conceived, designed, carried out, performed OLT, wrote manuscript and finalized the study. H.G. designed and performed the pathological examinations. GF.T. discussed the draft. H.B.Z. partly performed the experiments. SD.W. performed the analysis of data. XY.G animal caring. FZ.L. discussed the project. D.L. collected data. GY. C. funded and discussed the study. KD.C conceived and finalized the study.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-1505625/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1505625/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"The severe toxicities and side-effects derived from lifelong anti-rejection therapy following organ transplantation necessitates operational tolerance, a immunosuppression-free state in which the allograft functions well and no immunological rejections occur, no operational tolerance is in use globally. Here we introduce that operational tolerance, based on the hypertrophy to hyperplasia transition upon liver regeneration, is early acquired and permanently maintained in 50% adult rat liver allograft transplantation through the host bone marrow stem cell repopulation and 9-day cyclosporine A use. Compared with whole and partial liver transplantations as the controls, longer-term survivals (over 500 days) were observed in the tolerant hosts (p=0.001), the allograft functioned well and no acute or chronic rejections were confirmed by histology examinations. Further study revealed that the allograft was reinstituted by host-derived stem cells marked with CD34, which migrated, repopulated and differentiated after mobilization. However donor-specific hypo-response was not achieved through skin transplantation, indicating no adaptive immune activity occurrence. Our protocol is characteristic of targeting the allograft and non-immunological intervention, offering a novel avenue to operational tolerance induction which is of highly clinical relevance","manuscriptTitle":"The host bone marrow stem cell repopulation is crucial to the permanent tolerance in 50% liver transplantation","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-03-31 15:08:25","doi":"10.21203/rs.3.rs-1505625/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d165c86a-e5de-44b5-9aa0-bdacfff484d2","owner":[],"postedDate":"March 31st, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-03-31T15:08:27+00:00","versionOfRecord":[],"versionCreatedAt":"2022-03-31 15:08:25","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1505625","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1505625","identity":"rs-1505625","version":["v1"]},"buildId":"WrCJVZZCHTDjtuVLN7oU0","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}